Therapeutic re-appraisal of multiple drug resistant Salmonella typhi (MDRST) in Pakistani children

Journal of the Pakistan Medical Association

Volumn 52, Issue 3, 2002, Pages 123-127

  Hazir, T ^a   Qazi, S A ^a   Abbas, K A ^a   Khan, M A ^a  

^a Children Hospital Islamabad   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHILD; DEVELOPING COUNTRY; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; INFANT; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PAKISTAN; PREVALENCE; SALMONELLA TYPHI; TYPHOID FEVER;

AMOXICILLIN; CEFOTAXIME; CEFTRIAXONE; CHILD; CHILD, PRESCHOOL; CHLORAMPHENICOL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PAKISTAN; PROGNOSIS; RETROSPECTIVE STUDIES; SALMONELLA TYPHI; TREATMENT FAILURE; TREATMENT OUTCOME; TYPHOID FEVER;

EID: 0036271984     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Agarwal KC, Panhotra BR, Arya VK, et al. Typhoid fever due to chloramphenicol resistance Salmonella typhi associated with R-plasmid. Indian. J. Med Res. 1981:73:484-88.
2. Chun D, Seol SY, Cho DT et al. Drug resistance and R-plasmids in salmonella typhi isolated in Korea. Antimicrobe Agents, Chemother, 1977,11:209-13.
3. Olarte J, Galindo E. Salmonella typhi resistant to chloramphenicol, ampicillin and other antimicrobial agents: strains isolated during an extensive typhoid fever epidemic in Mexico.Antimicrob. Agents, Chemother., 1973:4:597-601.
4. Lepage P, Bogaerts J, Nsengumuremyi F, et al. Severe multiresistant salmonella typhimurium systemic infections in Central Africa - clinical features and treatment in a paediatric department J. Antimicrob. Chemother., 1984:14 (Suppl. B): 153-59.
5. Bhutta ZA, Naqvi SH, Razzaq RA, et al. Multidrug-resistant typhoid in cliildren: presentation and clinical features. RID., 1991,13: 832-36.
6. Anand AC, Kataria VK, Singh W, et al. An epidemic of multiresistant enteric fever in eastern India. Lancet, 1990: i. 352.
7. Wang F, Gu X Jin, Zhang MT, et al. Treatment of typhoid fever with oflaxacin. J. Antimicrob. Chemother., 1989: 23: 785-88.
8. Ahmed A, Salahuddin N, Ahsan T, et al. Enoxcin in the treatment of typhoid fever. Clin. Therapeutics, 1992:14: 825-28.
9. Rowe B, Ward IR, Threlfall EJ. Treatment of multiresistant typhoid fever. Lancet, 1991; 337; 1422.
10. Sharma A, Gathwala G. Clinical profile and outcome in enteric fever. Indian Pediatr., 1993: 30: 47-50.
11. Bavdekar A, Chaudhri M, Bhave S et al. Ciprofloxacm in typhoid fever. Indian. J. Pediatr., 1991,58:335-39.
12. Arora RK, Gupta A, Joshi NM, et al. Multidrug resistant typhoid fever: study of an outbreak in Calcutta. Indian. J. Pediatr., 1992. 29: 61-66.
13. Sen S, Goyal RS, Dev R. Ciprofloxacin in the management of multiple drug resistant typhoid fever. Indian. J. Pediatr., 1991;28: 417-19.
14. Dutta P. Ciprofloxacin for the treatment of severe typhoid fever in children. Pediatr. Infect. Dis. J., 1993: 12:971-72.
15. Cheesbrough JS, Mwema FI, Green SDR, et al. Quinolones in children with invasive salmonellosis. Lancet, 1991,338: 127.
16. Gulati S, Marwaha RK, Parkash D, et al. Multi-drug-resistant salmonella typhi - a need for therapeutic reappraisal. Ann. Trop. Paediatr., 1992; 12: 137-41.
17. Woodwards TE, Smadel JE, Ley HL Jr, et al. Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever. Ann. Intern. Med., 1948; 29: 131-34.
18. Girgis NI, Kilpatrick ME, Farid Z, et al. Cefixime in the treatment of enteric fever in children. Drugs Exp. Clin. Res., 1993;19:47-49.
19. Salam MA, Bennish M. Use of quinolones in childhood. J. Pediatr., 1989; 115: 1022-23.
20. Karande SC, Kashirsagar NA. Adverse drug reaction monitoring of Ciprofloxacin in pediatric practice. Indian. J. Pediatr., 1992; 29: 181-8.
21. Stahlmann R. Safety profile of the quinolones. J. Antimicrob Chemother., 1990:26:31-44.
22. Wolfson JS, Hooper DC. Overview of flouroquinolone safety. Am. J. Med., 1991;91 (Suppl. 6A):153S-161S.
23. Chsky V, Kapila K, Hullman R. et al. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use: emphasis on joint evaluation. Infection, 1991;19:289-96.
24. Iwai N, Nakamura H, Miyazu M. et al. Basic and clinical studies on norfloxacin in the pediatric field. Jap. J. Antibio., 1990,43:1629-48.
25. Schaad UB, Stoupis C, Wedgewood J, et al. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr. Infect. Dis., 1991; 10: 723-29.
26. Wahdan MH, Serie C, Cerisier Y, et al. Controlled field trial of live Salmonella typhi strain Ty21 a oral vaccine against typhoid :three year results. J. Infect. Dis., 1982;145:929-95.
27. Levine MH, Feniccio C, Black RE, Germanier R and Chilean Typhoid committee. Large scale field trial of Ty2: a live oral typhoid vaccine in enteric coated capsule formulation. Lancet, 1987; i: 1049-52.